Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,888.00
Bid: 6,887.00
Ask: 6,889.00
Change: 30.00 (0.44%)
Spread: 2.00 (0.03%)
Open: 6,927.00
High: 6,927.00
Low: 6,853.00
Yest. Close: 6,858.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

U.S. regulator says too many drugmakers chasing same cancer strategy

14 Jun 16 20:45

CORRECTED-U.S. regulator says too many drugmakers chasing same cancer strategy

(In June 10 story, corrects reference to AstraZeneca drug to PD-L1 instead of PD-1, paragraph 10) By Deena Beasley CHICAGO, June 10 (Reuters) - A new type of cancer drug that takes the brakes off the body's immune system has given drugmakers some remarkable wins against the deadly dis

14 Jun 16 20:44

BROKER RATINGS SUMMARY: UBS Double Upgrades Centrica To Buy From Sell

14 Jun 16 08:30

U.S. regulator says too many drugmakers chasing same cancer strategy

By Deena Beasley CHICAGO, June 10 (Reuters) - A new type of cancer drug that takes the brakes off the body's immune system has given drugmakers some remarkable wins against the deadly disease, but a top U.S. regulator says too many companies are focused on the same approach. Dr. Richa

10 Jun 16 11:00

Thursday broker round-up

(ShareCast News) - Fevertree Drinks: Berenberg upgrades to buy with a target price of 810p. AO World: JP Morgan keeps at neutral with a 200p target. WH Smith: JP Morgan stays at overweight with a target price of 1850p. Lancashire Holdings: UBS keeps at neutral with a target of 610p. Admiral Group

9 Jun 16 16:34

UPDATE 1-AstraZeneca sells rights to anaesthetics for up to $770 mln

* Aspen acquires non-U.S. rights to seven established drugs * Latest in run of externalisation deals by AstraZeneca * Aspen shares jump 10 percent, AstraZeneca stock slips (Adds context on externalisation drive, market reaction) By Ben Hirschler LONDON, June 9 (Reuters)

9 Jun 16 07:56

AstraZeneca in $770m deal with Aspen Group

(ShareCast News) - AstraZeneca said it has entered a $770m commercialisation deal with Aspen Global Incorporated (AGI), part of the the US Aspen Group, for rights to its global anaesthetics portfolio outside the US. Under the terms of the agreement, AGI will acquire the commercialisation rights, out

9 Jun 16 07:36

AstraZeneca sells rights to anaesthetics to South Africa's Aspen

LONDON, June 9 (Reuters) - AstraZeneca said on Thursday it had agreed to sell the commercialisation rights for its portfolio of anaesthetics outside the United States to South Africa's Aspen Pharmacare for an initial payment of $520 million. The agreement covers seven established medicines

9 Jun 16 06:22

TOP NEWS: AstraZeneca In USD770 Million Anaesthetics Deal With Aspen

9 Jun 16 06:11

AstraZeneca completes Zurampic deal with Ironwood

(ShareCast News) - Drugmaker AstraZeneca continued its charge of licensing its Zurampic (lesinurad) drug on Friday, with the company announcing it has completed its licensing agreement with Ironwood Pharmaceuticals for the exclusive United States rights to the drug. The FTSE 100 firm said the agreem

3 Jun 16 07:52

UPDATE 1-GSK seeks lead in triple lung drug market with 2016 filing plan

* U.S. filing by end 2016 vs first half 2018 seen previously * Rivals in triple drug space include AstraZeneca, Novartis (Adds more details on competitive market) By Ben Hirschler LONDON, June 2 (Reuters) - GlaxoSmithKline moved to consolidate its lead in a new class of three-

2 Jun 16 08:00

AstraZeneca signs major deal with Grunenthal over Zurampic

(ShareCast News) - Pharmaceutical and biologics company AstraZeneca announced on Thursday that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America. The FTSE 100 firm received approval from the European Medicines

2 Jun 16 07:08

AstraZeneca sells EU, Latam gout drug rights to Gruenenthal

LONDON, June 2 (Reuters) - AstraZeneca has sold the European and Latin American rights to its new gout drug Zurampic to private German drugmaker Gruenenthal for up to $230 million, following a similar disposal of U.S. rights to the medicine. The British group said on Thursday up it would re

2 Jun 16 06:52

TOP NEWS: AstraZeneca Set For USD230 Million From Licensing Zurampic

2 Jun 16 06:16

Sunday newspaper round-up: AstraZeneca, oil IPOs, M&S, Exova, Tesco

(ShareCast News) - AstraZeneca, the UK's second-biggest drug developer, will this week outline its next big hope in the battle against cancer by unveiling new data on a class of treatments, known as DNA damage response (DDR) medicines, at a conference in Chicago. The drugs work by stopping cancerous

29 May 16 16:22

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.